18 slides from Teva Pharmaceutical Industries's technical presentation, Jul 7, 2026
Slide 1: TEV-'408 (Anti-IL-15) Vitiligo Phase 1b 24-Week Efficacy Results
TEV-’408(Anti-IL-15) Vitiligo Phase 1b 24- Week Efficacy Results July 7, 2026
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our futu
Slide 3: President and Chief Executive Officer
President and Chief Executive Officer 3|
Slide 4: Key anticipated milestones for 2026
Assets Key anticipated milestone for 2026 Timing duvakitug UC/CD Phase 2 maintenance data H1’26 ecopipam Filed with the FDA H1’26 Vitiligo Phase 1b topline results H1'26 Anti-IL-15 Celiac Phase 2a topline results H2'26 DARI Targeted completion of pivotal Phase 3 studies H2'26 (ICS/SABA) emrusolmin P
Slide 5: Late-stage pipeline assets
Late-stage pipeline assets Peak sales Estimated Ambition to grow and accelerate pipeline Targeted submission potential1 Market size2 olanzapine LAI Schizophrenia Preparing for launch LAI franchise ecopipam Tourette Syndrome Preparing for launch Phase 3 DARI (ICS-SABA) Enrollment completed for Asthma
Slide 6: Executive Vice President, Global R&D & Chief Medical Officer
Executive Vice President, Global R&D & Chief Medical Officer 6|
Slide 7: Large Unmet Need for Patients with Vitiligo
Large Unmet Need for Autoimmune disease that causes loss of pigment Patients with Vitiligo cells, melanocytes, leading to white patches • Autoimmune disease destroys melanocytes, causing unpigmented skin patches • Affects all ages and skin types; ~0.5–2% global prevalence, many undiagnosed • Heavy p
Slide 8: Teva internally discovered TEV-'408 to inhibit IL-15
Teva internally discovered TEV-’408 to inhibit IL-15 8| Source: Medical literature review and Teva internal analysis
Slide 9: TEV-'408 serum levels and early evidence of IL-15 blockade
Clinical data show prolonged antibody half-life and sustained suppression of free IL-15, supporting the potential for infrequent dosing TEV-’408 Serum Levels Early evidence of IL15 blockade Following SD administration in healthy volunteers Free IL-15 in Phase I in healthy volunteers Mean Free IL15 c
Slide 10: End of treatment efficacy data shared today
End of treatment efficacy data shared today • The study enrolled patients with active or stable non-segmental vitiligo Anti-IL-15 SC End of Treatment • Anti-IL-15 was administered as two Efficacy subcutaneous injections at time 0 and at Time 0 Week 12 Week 24 Week 40 Week 80 week 12 • VASI, Vitiligo
Slide 11: How T-VASI and F-VASI are scored
1 Map the Regions 2 Measure the Area 3 Grade Depigmentation 4 Calculate the Score F-VASI F-VASI Area in fingertip Face treated as a units for small dedicated region. facial patches. T-VASI T-VASI Grade how white each patch is, Multiply area × Body divided into Area in hand units – from 0% to 100%. d
Slide 12: Well-tolerated with no safety signals observed to date
Well-tolerated with no safety signals observed to date Patient-reported outcomes TEV-53408 Patient Global Impression (PGIC) of Change for Response Rates Vitiligo Week 24 Phase 1b · Week 24 N=38 Facial PGIC Improved ~75%* Inclusion F-VASI > 0.5 OR T-VASI ≥ 5 Total PGIC Improved ~55% Dosing SC q12 wee
Slide 13: Response Rates: TEV-53408 Phase 1b Week 24 vs upadacitinib
TEV-53408 upadacitinib Response Rates Phase 1b Week 24 Phase 2 Week 24 N=38 N=47 N=43 Study Population F-VASI > 0.5 OR T-VASI ≥ 5 F-VASI ≥ 0.5 AND T-VASI ≥ 5 Dosing SC q12 weeks Oral 11 mg daily Oral 22 mg daily F-VASI50* 42% 38.3% 39.5% F-VASI75* 21% 19.1% 14.0% T-VASI50* 7% 6.4% 11.6% • F-VASI50 (
Slide 14: Treatment landscape and unmet need in vitiligo
Treatment landscape – high unmet need due to lack of systemic therapies with favorable safety profiles and convenient dosing – mirrors other dermatological conditions like psoriasis and atopic dermatitis which were transformed by biologics Vitiligo1: Penetration of adv. systemic therapies in select
Slide 15: IL-15 biology and expansion indications
Bone marrow Skin epidermis Hair follicle Gut epithelium PATIENT INDICATIONS POPULATION* Celiac 1.6M Gastroenterology Eosinophilic Esophagitis 0.6M IL-15 Vitiligo 4.1M Dermatology Alopecia Areata 2.1M Atopic Dermatitis 23.9M List illustrative and not exhaustive Antigen-presenting NK cells T cells cel
Slide 16: Teva-Discovered TEV-'408 Targets IL-15 and is Designed for Quarterly SC Dosing
Teva-Discovered TEV-’408 Targets IL-15 and is Designed for Quarterly SC Dosing Accelerated anti-IL-15 vitiligo clinical plan pulls BLA into 2031 Differentiated Profile Clinical Data Path & Expansion • Internally developed, potential • Encouraging clinical • Rapid path to submission in best-in-class
Slide 17: Q&A
Q8A
Slide 18: We are all in for better health
v We are all in for better health